Hepatic lipase, encoded by the LIPC gene¹¹ LIPC gene
Lipase C, hepatic type — LIPC gene on chromosome 15q22 encodes the enzyme responsible for hydrolysing triglycerides and phospholipids in circulating lipoproteins on chromosome 15, is a lipolytic enzyme synthesized in hepatocytes and anchored to liver sinusoidal endothelial cells. It serves two linked roles: converting the larger, cholesterol-rich HDL2 particles into smaller HDL3 particles (a catabolic step in the reverse-cholesterol transport cycle) and facilitating selective cholesterol ester uptake from IDL and LDL remnants into the liver. Higher hepatic lipase activity lowers circulating HDL cholesterol; lower activity raises it.

The Mechanism

rs11857380 is an intronic variant located within LIPC intron 1, and it is in linkage disequilibrium²² linkage disequilibrium
Linkage disequilibrium — non-random co-inheritance of nearby alleles on the same chromosome; when two variants are in strong LD, one reliably tags the other across populations with the well-characterised LIPC locus HDL-associated signals, including the promoter variant rs10468017 (also known as the LIPC −250G>A-region haplotype tag) and the promoter variant rs1800588 (−514C>T). These promoter variants alter the binding of transcription factors — in particular sterol-regulatory and sex-hormone-responsive elements — to the LIPC promoter, reducing LIPC transcriptional output by approximately 30% in carriers of the HDL-raising haplotype. Lower LIPC mRNA → less hepatic lipase protein → reduced hydrolysis of HDL2 phospholipids → accumulation of larger, more cholesterol-rich HDL2 particles and elevated plasma HDL cholesterol.

The G allele at rs11857380 tags this HDL-raising haplotype. Carriers of the G allele have, on average, 1.5–3.5 mg/dL higher HDL cholesterol per G allele, consistent with the effect sizes reported for the linked promoter variants across multiple populations.

The Evidence

A genome-wide association study of advanced AMD³³ genome-wide association study of advanced AMD
Neale et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). PNAS, 2010 identified the LIPC locus as protective for advanced age-related macular degeneration (AMD), with the functional promoter variant rs10468017 showing OR 0.82 per HDL-raising allele (P=1.34×10⁻⁸). The associated replication study⁴⁴ associated replication study
Neale et al. Associations of smoking, BMI, lutein, and LIPC rs10468017 with advanced AMD. IOVS, 2011 showed TT homozygotes at the LIPC locus had the strongest protection against advanced AMD (OR 0.70, P=1.8×10⁻³), with the effect appearing to be at least partly independent of circulating HDL levels, suggesting a direct retinal lipid metabolism role for hepatic lipase.

In terms of HDL genetics, the well-validated promoter variant rs1800588 (in strong LD with rs11857380 through the same haplotype block) raises HDL cholesterol by approximately 1.5 mg/dL per minor allele copy and 3.5 mg/dL in homozygous minor-allele carriers in European populations, confirmed in a systematic meta-analysis⁵⁵ systematic meta-analysis
Souverein et al. Genetic-epidemiological evidence on genes associated with HDL cholesterol. Eur J Cardiovasc Prev Rehab, 2003 of over 24,000 participants. The LIPC intron 1 haplotype study⁶⁶ LIPC intron 1 haplotype study
Hiura et al. Association of an intronic haplotype of LIPC with hyperalphalipoproteinemia. J Hum Genet, 2008 replicated significant associations between specific LIPC intronic haplotypes and hyperalphalipoproteinemia (elevated HDL >75th percentile) in two independent Japanese cohorts.

Sex-specific effects have been reported: the Guerra et al. study⁷⁷ Guerra et al. study
Guerra et al. LIPC variants in the promoter and intron 1 modify HDL-C levels in a sex-specific fashion. Atherosclerosis, 2009 found that in women, the minor allele of the linked LIPC intron 1 variant rs261342 was associated with an approximately 14% increase in HDL-C and a 30% reduced risk of low HDL, while associations in men were considerably weaker. This sex-hormone interaction — likely mediated by estrogen suppression of hepatic lipase transcription — means that premenopausal women may already have partially suppressed LIPC activity regardless of genotype.

The relationship between LIPC-elevated HDL and cardiovascular disease is not straightforward. While higher HDL generally correlates with lower CVD risk in observational studies, Mendelian randomization analyses have shown that genetically elevated HDL through the LIPC pathway does not uniformly translate to reduced coronary heart disease, likely because hepatic lipase activity also affects IDL remnant clearance and postprandial triglyceride metabolism — pathways with opposing cardiovascular effects.

Practical Actions

Carriers of the G allele at rs11857380 tend to have modestly elevated HDL cholesterol. For TG heterozygotes, the effect is approximately 1–2 mg/dL higher HDL on average. For GG homozygotes, the elevation may reach 3–4 mg/dL above average. This small but consistent benefit is worth confirming with a fasting lipid panel, which also captures triglycerides and LDL — both of which can independently signal metabolic risk even when HDL is elevated.

Carriers of two T alleles (TT) have average hepatic lipase activity and average HDL levels. Their HDL-C is more diet-responsive: dietary fat quality (polyunsaturated vs. saturated) influences HDL particle composition more noticeably in high-HL-activity individuals. Prioritizing omega-3-rich fish, olive oil, and avoiding trans fats can offset the absence of the genetic HDL-raising effect.

Interactions

The LIPC HDL-raising signal at rs11857380 interacts with CETP variants⁸⁸ CETP variants
CETP — cholesteryl ester transfer protein facilitates exchange of cholesterol esters from HDL to VLDL; strong LD with rs708272 (TaqIB) — individuals with both reduced CETP activity and reduced hepatic lipase activity accumulate the largest HDL2 particles. This combined effect has been studied in the context of HDL functional quality, since very large HDL particles (common in CETP + LIPC compound low-activity carriers) may paradoxically have reduced cholesterol efflux efficiency. See rs708272 (CETP TaqIB) for the complementary variant.

Hepatic lipase activity also modulates the efficiency of statin therapy on HDL: in individuals with lower baseline LIPC expression (G allele carriers), statin-induced HDL increases may be blunted because the HDL-raising pathway is already partially activated. Conversely, fibrate therapy (fenofibrate, gemfibrozil) raises HDL partly by reducing VLDL-derived triglyceride substrate for hepatic lipase, an effect that may be more prominent in TT carriers with normal-high HL activity.

The thyroid stimulating hormone receptor sits at the centre of the thyroid axis. TSH released by the pituitary binds TSHR on thyroid follicular cells, driving production of T3 and T4. In Graves' disease — the most common autoimmune cause of hyperthyroidism — the immune system generates stimulating autoantibodies (TRAbs) that bind TSHR and permanently mimic TSH, overriding the pituitary's feedback control. rs12101255 is an [intronic regulatory SNP | A variant within a non-coding intron that influences when, where, and how much of the TSHR protein is made] in intron 1 of TSHR that influences whether the thymus — the organ where immune self-tolerance is trained — adequately presents TSHR to developing T cells. When TSHR expression in the thymus is reduced, autoreactive T cells that would normally be deleted can escape into the circulation, where they can seed the autoimmune response.

The Mechanism

TSHR intron 1 contains a regulatory element that controls tissue-restricted expression of the receptor, including in thymic epithelial cells. A landmark 2014 PNAS study by Stefan et al.¹¹ Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity identified an open chromatin region overlapping rs12101255 and the adjacent rs12101261 in this intron. In cells stimulated with interferon-alpha — released during viral infection — histone H3 lysine 4 methylation (H3K4me1) is enriched at this region, and the transcriptional repressor PLZF binds specifically at the disease-susceptibility allele. The net effect: individuals carrying the risk genotype show measurably reduced intrathymic TSHR expression compared with protective-allele carriers. Fewer TSHR-presenting thymic cells means fewer autoreactive T cells are clonally deleted, allowing them to persist and, under the right environmental trigger, attack the thyroid.

This also explains the well-known viral-trigger pattern in Graves' disease: interferons induced by viral infection epigenetically activate PLZF binding at the risk allele, acutely suppressing thymic TSHR, and providing a mechanistic link between infection and autoimmune onset.

The variant also correlates with reduced full-length TSHR mRNA relative to splice variants in thyroid tissue itself, suggesting dual dysregulation — both in tolerance training and in the receptor's eventual expression in the thyroid.

The Evidence

The rs12101255–Graves' disease association was established convincingly by Brand et al. in Human Molecular Genetics²² Brand et al. in Human Molecular Genetics
A systematic SNP analysis across an 800 kb region spanning TSHR, 768 GD cases and 768 matched controls, European descent (2009): OR 1.55, 95% CI 1.33–1.81, P = 1.95×10⁻⁷. The risk direction was replicated in three independent European cohorts by Płoski et al.³³ Płoski et al.
Warsaw, Gliwice, and UK cohorts; the UK arm alone comprised 2,504 patients and 2,784 controls — one of the largest single-study samples for this locus (2010), with ORs of 1.47–1.87 and p-values reaching 3.68×10⁻²¹.

A meta-analysis of seven articles (5,754 GD cases, 5,768 controls)⁴⁴ meta-analysis of seven articles (5,754 GD cases, 5,768 controls)
Including Chinese, Japanese, Polish, UK, and Brazilian populations quantified the per-genotype risk: T vs C allele OR 1.50 (95% CI 1.40–1.60); TT vs CC OR 2.22 (95% CI 1.92–2.57); carriers of at least one T allele (CT+TT) had OR 1.66 versus CC. A second large meta-analysis from 2016 (4,790 cases, 5,350 controls) confirmed TT+CT vs CC OR 1.67 (95% CI 1.53–1.83, I²=0%), with no between-study heterogeneity — an unusually consistent cross-population signal.

The variant does not appear to differentiate Graves' disease from Graves' ophthalmopathy (the eye manifestation): the SNP predicts overall Graves' susceptibility but not the orbital complication specifically.

Practical Actions

TT homozygotes face approximately 2.2-fold elevated Graves' disease risk. Graves' disease is highly treatable — the priority for TT and CT carriers is early recognition of hyperthyroid symptoms rather than prophylaxis, and awareness of triggers including viral illness and excess iodine intake.

Thyroid peroxidase antibodies (TPO-Ab) and TSH receptor antibodies (TRAb) are the earliest detectable biomarkers of thyroid autoimmunity, often present years before clinical hyperthyroidism. TT carriers benefit from knowing their baseline thyroid function and antibody status.

Selenium at 100–200 mcg/day has been shown in RCTs to reduce autoimmune thyroid activity and TRAb titres. Since the TSHR intron 1 risk variants appear to lower the immune tolerance threshold specifically at this antigen, reducing the overall autoimmune burden through selenium's immunomodulatory effects is a targeted intervention for T allele carriers.

Interactions

rs12101255 and rs179247 are the two most-studied SNPs in TSHR intron 1; they are in linkage disequilibrium and are frequently studied as a haplotype pair. Carrying risk alleles at both loci may carry higher Graves' disease susceptibility than either alone. rs12101261, the immediately adjacent SNP that shares the same open chromatin region, is structurally the closest functional partner.

Beyond the TSHR locus, Graves' disease has strong HLA associations (DRB1, DQA1), PTPN22 R620W (rs2476601), and CTLA4 variants (rs3087243, rs231775) as independent susceptibility loci — these act through T-cell activation thresholds independently of the thymic TSHR expression mechanism captured by rs12101255.

Every cell in the body needs zinc for more than 300 enzymes and 2,000+ transcription factors, yet the human body has no dedicated zinc storage organ — it must be continuously absorbed from food. In the intestine, most of that absorption flows through a single gateway: ZIP4¹¹ ZIP4
The Zrt/Irt-like protein 4, encoded by SLC39A4 on chromosome 8q24.3, is the primary zinc importer on the apical surface of duodenal and jejunal enterocytes. When both copies of the SLC39A4 gene are non-functional, dietary zinc simply cannot cross the gut wall. The result — hereditary acrodermatitis enteropathica (AE) — is a severe systemic zinc deficiency that is uniformly fatal without treatment but fully manageable with lifelong oral zinc supplementation.

The rs121434288 variant (c.1576G>A on the coding strand; C>T on the GRCh38 plus strand) replaces glycine at position 501 of the mature ZIP4 protein with arginine. Glycine 501 sits within the fifth transmembrane domain of ZIP4, adjacent to a histidine residue at position 536 that is conserved throughout the ZIP transporter family and essential for zinc coordination. The Gly→Arg substitution introduces a bulky, positively charged residue into the membrane-spanning helix, almost certainly disrupting the protein's three-dimensional structure and eliminating zinc transport activity.

The Mechanism

ZIP4 is expressed on the apical (luminal-facing) membrane of enterocytes, with expression upregulated in response to zinc deficiency. Its function is to move zinc ions from the intestinal lumen into the absorptive cells, from where zinc enters the circulation. The Gly501Arg missense disrupts the structural integrity of ZIP4's transmembrane channel. Because AE is autosomal recessive²² autosomal recessive
Both copies of the gene must be non-functional for disease to occur; one functional copy is sufficient for normal zinc absorption, a single defective copy has no measurable impact on zinc status. Homozygotes — who inherit the variant from both parents — lose all functional ZIP4 activity, reducing intestinal zinc absorption to a fraction of normal. Since the body cannot synthesize or store meaningful zinc reserves, systemic zinc deficiency develops rapidly, within the first weeks of life in affected infants.

The Evidence

Küry et al. (2002)³³ Küry et al. (2002)
Küry S et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nature Genetics, 2002 identified SLC39A4 as the AE gene through positional cloning and mutational analysis of eight affected families. The Gly501Arg variant (reported in their study as c.1501G>A in the then-current reference sequence; now annotated as c.1576G>A / p.Gly526Arg in isoform 2, or p.Gly501Arg in the canonical isoform) was found in homozygous form in two brothers with classic AE phenotype. The authors noted the variant's location near the conserved His536 residue known to be required for metal co-ordination in ZIP-family transporters.

A comprehensive mutation update by Schmitt et al. (2009)⁴⁴ Schmitt et al. (2009)
Schmitt S et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Human Mutation, 2009 catalogued 31 pathogenic SLC39A4 variants across AE patients, confirming that missense mutations are the most common type and are distributed throughout the gene. The Gly501Arg variant is among the most structurally damaging — the substitution of glycine (the smallest amino acid, enabling tight membrane helix packing) with arginine (large and positively charged) in a transmembrane segment is predicted to severely disrupt ZIP4 folding and function.

Clinically, untreated AE presents in formula-fed infants within the first 4–10 weeks of life with a triad of acral and perioral dermatitis, diarrhoea, and alopecia. Breast-fed infants are typically protected by the high bioavailability of zinc in breast milk and present upon weaning. Without zinc supplementation, affected infants fail to thrive and the disease is fatal.

Practical Implications

Oral zinc supplementation fully corrects the phenotype in homozygous AE patients. Treatment is initiated at 5–10 mg/kg/day of elemental zinc during the acute phase, then reduced to a maintenance dose of 1–2 mg/kg/day for life. Doses must be adjusted upward during growth phases, illness, and pregnancy. Regular monitoring of serum zinc is essential to avoid both deficiency relapses and zinc toxicity from over-supplementation.

Carriers (heterozygotes) are clinically unaffected under normal dietary conditions, but this variant is important for family planning: two carrier parents have a 25% probability of having an affected child with each pregnancy.

Interactions

AE illustrates how completely the body's zinc economy depends on ZIP4. Variants in other SLC39A (ZIP family) and SLC30A (ZnT family) genes modulate zinc homeostasis but do not cause AE. Dietary factors that affect zinc bioavailability — particularly phytates in cereals and legumes, which form insoluble zinc complexes — are especially relevant for heterozygous carriers whose single functional ZIP4 copy must work efficiently. Co- administration of oral zinc with quinolone antibiotics (ciprofloxacin) or tetracyclines (doxycycline) should be timed to avoid chelation interactions that reduce absorption of both compounds.

Antithrombin is the body's principal brake on coagulation — a serine protease inhibitor¹¹ serine protease inhibitor
Serpins (serine protease inhibitors) are a superfamily of proteins that inactivate serine proteases by acting as suicide substrates. Antithrombin targets thrombin and factor Xa, the two key amplifiers of the clotting cascade. that directly quenches thrombin and factor Xa, the central enzymes of the coagulation cascade. Without adequate antithrombin activity, clot formation goes unchecked, and blood can clot in veins or arteries where it should not. The rs121909548 variant — known as Antithrombin Cambridge II or A384S — is the single most prevalent cause of hereditary antithrombin deficiency in European populations, found in approximately 1 in 880 people of British descent.

What makes Cambridge II unusual among hereditary thrombophilias is how it hides: routine antithrombin antigen tests often return normal results because the variant protein is secreted and circulates at normal plasma concentrations. The defect only becomes apparent in functional assays measuring heparin-catalysed thrombin inhibition. This leads to systematic under-diagnosis²² systematic under-diagnosis
In clinical practice, antithrombin deficiency is typically screened with anti-Xa activity assays; Cambridge II can produce results at the borderline of the normal range and is often missed unless a specific substrate assay or genetic test is performed. and, consequently, many carriers are not identified until after their first thrombotic event.

The Mechanism

The p.Ala416Ser substitution (coding-strand notation c.1246G>T; on the plus strand NC_000001.11:g.173904038C>A) places a serine where alanine-384 normally sits in the reactive site loop³³ reactive site loop
The reactive site loop (RSL) is the bait segment of antithrombin that mimics a protease cleavage site. Thrombin bites the RSL, becomes covalently trapped, and is inactivated. Heparin binding induces a conformational change that dramatically accelerates this trapping. of the protein.

Crystallographic analysis by Huntington et al. (2003)⁴⁴ Crystallographic analysis by Huntington et al. (2003)
Huntington JA et al., Blood 2003 — X-ray crystal structures of Cambridge II antithrombin in complex with heparin and a heparin mimetic; showed the A384S substitution repositions the reactive centre loop P14 residue, favouring insertion into the A-sheet rather than trapping thrombin revealed the structural consequence: in the presence of heparin, the A384S substitution causes the reactive-site loop to adopt a "substrate" conformation rather than an inhibitory one. Instead of trapping thrombin in an irreversible complex, the variant antithrombin is cleaved by thrombin and released — effectively feeding thrombin rather than neutralising it. The result is that heparin, normally antithrombin's most powerful accelerant, loses much of its ability to enhance Cambridge II antithrombin's inhibitory activity.

In plasma, this translates to a type II reactive-site (type IIRS) defect: functional antithrombin activity (measured as heparin-dependent inhibition of thrombin or factor Xa) is reduced, while the antigen concentration is normal or near-normal. Heterozygous carriers have approximately 60–80% of normal functional antithrombin activity; the remaining activity comes from the normal allele alone.

The Evidence

VTE risk: The definitive population study by Corral et al. (Blood, 2007)⁵⁵ Corral et al. (Blood, 2007)
Corral J et al., Blood 2007 — Spanish case-control study of 479 unselected VTE patients and 477 matched controls; genotyped all participants for A384S; also surveyed 9,669 West Scotland blood donors for population prevalence found the A384S allele in 1.7% of VTE patients versus 0.2% of controls, yielding an adjusted odds ratio of 9.75 (95% CI 2.2–42.5) for venous thrombosis. In their survey of 9,669 West Scotland blood donors, 10 carriers were identified — a prevalence of 1.14 per 1,000 — establishing Cambridge II as the most frequent single cause of hereditary antithrombin deficiency in the British population.

Arterial thrombosis: Roldán et al. (2009)⁶⁶ Roldán et al. (2009)
Roldán V et al., Thromb Haemost 2009 — case-control study of 303 myocardial infarction patients and 303 matched controls in southern Spain; genotyped for A384S and traditional cardiovascular risk factors showed that Cambridge II carriers have a 5.66-fold increased risk of myocardial infarction (95% CI 1.53–20.88; p=0.009) after adjusting for sex and conventional cardiovascular risk factors, indicating that the thrombotic risk is not limited to veins.

Thrombin generation: Marlar et al. (2008)⁷⁷ Marlar et al. (2008)
Reference for thrombin generation data in Cambridge II carriers — endogenous thrombin potential studies demonstrated measurable increases in endogenous thrombin potential in Cambridge II heterozygotes, providing a mechanistic link between the functional antithrombin defect and the prothrombotic clinical phenotype observed in population studies.

Clinical penetrance: The Cambridge II mutation has appreciable but incomplete penetrance. Not every carrier develops thrombosis. Thrombotic events are often triggered by secondary risk factors — surgery, immobility, oral contraceptives, pregnancy — that push clotting risk above the threshold at which reduced antithrombin activity becomes clinically decisive.

Practical Actions

The key priorities for Cambridge II carriers are: (1) ensure the diagnosis is confirmed by a functional antithrombin assay (not antigen alone), (2) manage situational thrombotic triggers proactively, (3) obtain hematology input before high-risk procedures, and (4) extend cascade testing to first-degree relatives.

Standard anticoagulants (heparin, warfarin, DOACs) remain effective, though unfractionated heparin and LMWH require larger-than-usual doses to achieve therapeutic effect in some carriers because their circulating Cambridge II antithrombin is heparin-resistant. Antithrombin concentrate is available for use during high-risk situations such as surgery and delivery in symptomatic carriers.

Interactions

Cambridge II adds independently to other thrombophilic risk variants. Carriers who also have factor V Leiden (rs6025), prothrombin G20210A (rs1799963), or protein C/S deficiency are at substantially higher combined VTE risk than any single variant predicts — this is one of the best-studied gene-gene interactions in thrombophilia. Oral contraceptives containing estrogen multiply VTE risk several-fold in antithrombin-deficient carriers and are a particular concern for female carriers of reproductive age.

Coagulation factor XI (FXI) occupies a paradoxical position in the blood clotting system. It amplifies thrombin generation inside growing clots, stabilizes fibrin networks against premature dissolution, and maintains hemostasis in tissues where the body's own clot-dissolving enzymes work aggressively. Yet people who lack FXI entirely rarely bleed spontaneously — their bleeding emerges primarily after surgery, dental procedures, or trauma, concentrated in the mouth, throat, and urinary tract. And in a remarkable cardiovascular twist, their absent FXI protects them against ischemic stroke and deep-vein thrombosis at rates that have made FXI one of the most actively pursued anticoagulation drug targets in the world.

The Glu117Stop mutation is the most prevalent cause of this condition in the Ashkenazi Jewish population. Originally named for the glutamic acid at position 117 of the mature FXI protein (current HGVS nomenclature calls it p.Glu135Ter, counting from the signal peptide initiator), it was identified by Asakai et al. in 1991¹¹ Asakai et al. in 1991
Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med, 1991 as one of two ancient founder mutations that together account for approximately 96% of defective F11 alleles in this population. The heterozygote carrier frequency among Ashkenazi Jews is approximately 1 in 8 — making this one of the most common inherited bleeding disorders in any single ancestral group.

The Mechanism

The c.403G>T substitution converts the codon for glutamic acid at position 135 (mature protein position 117) into a stop codon (TAA). The resulting transcript is predicted to undergo nonsense-mediated mRNA decay²² nonsense-mediated mRNA decay
NMD is a cellular surveillance mechanism that degrades mRNAs carrying premature stop codons before significant abnormal protein can accumulate; most nonsense variants early in a transcript trigger NMD rather than producing a truncated peptide, leaving no functional FXI protein from the affected allele.

In heterozygous carriers, the intact F11 allele compensates partially, producing roughly 50% of normal FXI activity — typically 20–70 U/dL versus the normal range of 60–150 U/dL. Homozygous carriers produce essentially no FXI, with activity below 15 U/dL — the diagnostic threshold for severe FXI deficiency (hemophilia C or Rosenthal syndrome).

FXI's role in coagulation is primarily in the thrombin feedback loop³³ thrombin feedback loop
Once initial clot formation begins, thrombin circles back to activate more FXI, creating a self-amplifying cycle that deepens fibrin cross-linking and also activates TAFI — an inhibitor of clot dissolution — shielding the clot from fibrinolysis. Because FXI is not essential for the immediate hemostatic response at the moment of vessel injury (the extrinsic pathway covers initial thrombin generation), its absence goes unnoticed under ordinary circumstances. The deficiency is exposed when bleeding occurs in tissues with vigorous local fibrinolytic activity — dental sockets, tonsillar beds, the urogenital tract — where the fibrin-dissolving machinery is simply too powerful for a FXI-deficient clot to resist.

The Evidence

The cardiovascular paradox of FXI deficiency is among the best-documented genotype-protection relationships in hematology. In a study of 115 patients aged 45 or older with severe FXI deficiency⁴⁴ 115 patients aged 45 or older with severe FXI deficiency
Salomon et al., Blood 2008; compared against expected stroke incidence derived from a national stroke survey, only one ischemic stroke was observed against an expected 8.56 (P=.003) — an approximately eight-fold reduction. Notably, no protective effect was seen for myocardial infarction, consistent with FXI's stronger contribution to fibrin-rich venous and cerebral thrombi than to the platelet-rich arterial plaques that cause heart attacks.

Deep-vein thrombosis protection is equally striking. A companion study of 219 severe FXI-deficient patients⁵⁵ 219 severe FXI-deficient patients
Salomon et al., Thrombosis and Haemostasis 2011; zero DVT events compared to 4.68 expected found zero DVT events versus 4.68 expected from population data — a result consistent across three additional control datasets from population-based studies.

Bleeding risk is real but unpredictable. In the largest perioperative series to date, 198 FXI-deficient patients underwent 252 surgical and obstetric procedures⁶⁶ 198 FXI-deficient patients underwent 252 surgical and obstetric procedures
Handa et al., Blood Advances 2023; Mount Sinai Health System 2011–2021; 13% of procedures had bleeding events. Personal history of bleeding was the strongest predictor (OR 5.92, P=.001) — not FXI activity level. An FXI level above 40 U/dL had reasonable specificity (75%) for predicting lower bleeding risk but poor sensitivity (47%), confirming that genotype and activity level alone cannot determine individual bleeding risk.

Phenotypic severity differs between the two Ashkenazi founder variants. Type II homozygotes (Glu117Stop)⁷⁷ Type II homozygotes (Glu117Stop)
Asakai et al. 1991 — mean FXI activity 1.2% vs 9.7% for Type III; Type II homozygotes had more bleeding episodes have lower residual FXI activity and more bleeding episodes than Type III (Phe283Leu) homozygotes. Compound heterozygotes (one Type II + one Type III allele) show intermediate activity of approximately 3.3%.

Practical Actions

The critical clinical window for FXI deficiency management is before a planned procedure, not after bleeding starts. First-line prophylaxis for dental procedures and minor oral surgery is tranexamic acid mouthwash (4.8% solution, 4×/day for 5–7 days post-procedure), which blocks fibrinolysis locally without requiring systemic coagulation factor replacement. For major surgery, fresh frozen plasma (FFP) raises FXI levels; FXI concentrate (available in some countries, including the UK and Israel) offers more controlled dosing. A critical ceiling: FXI replacement above 70 U/dL carries paradoxical thrombotic risk — the same protein's absent version is cardioprotective, and over-correcting the deficiency can flip the balance.

The Ashkenazi Jewish population context is important for family planning: with a heterozygote frequency of ~1 in 8, partner carrier testing is strongly recommended for Ashkenazi Jewish individuals who carry this variant. If both partners carry a defective F11 allele, the offspring risk of severe homozygous deficiency is 1 in 4.

Interactions

The Type II (Glu117Stop) mutation is compound-heterozygous with the Type III (Phe283Leu; rs121965064) mutation in a substantial fraction of Ashkenazi Jewish patients with severe FXI deficiency. Compound heterozygotes show intermediate FXI activity (~3.3%) and intermediate bleeding phenotype between Type II and Type III homozygotes. When this variant is found in conjunction with a second F11 null allele (from rs1057516616 frameshift or rs1057517151 frameshift, for example), the resulting severe deficiency carries the same management requirements as homozygous Glu117Stop.

The FXI cardiovascular protection intersects meaningfully with prothrombotic variants. A carrier of this variant who also carries Factor V Leiden (rs6025) or the prothrombin G20210A mutation (rs1799963) faces an uncertain net coagulation balance — the FXI deficiency may partially offset the thrombophilic risk, but this interaction has not been studied rigorously and specialist hematology assessment is needed rather than assuming either variant dominates.

Deep in chromosome 16, a single gene quietly coordinates two of the body's most vital systems: blood cell production and cardiac structure. ZFPM1 encodes FOG1 (Friend of GATA 1)¹¹ FOG1 (Friend of GATA 1)
a transcriptional cofactor that partners with GATA transcription factors to drive erythroid and megakaryocyte differentiation. Without functional FOG1, developing red blood cells stall at the proerythroblast stage and fail to mature, while megakaryocytes — the precursors of platelets — also depend on FOG1 for normal differentiation. In the heart, FOG1 cooperates with GATA-4/5/6 transcription factors to shape the outlet tract and atrioventricular valves; mice conditionally lacking endothelial FOG1 develop double outlet right ventricle and valve malformations and die at embryonic day 14.5.

The rs12232375 variant sits within intron 2 of ZFPM1 at chromosome 16q24.2, approximately 10,850 bases from the nearest exon boundary (NM_153813.3:c.268+10850G>C). It is a regulatory tag SNP — not a protein-altering change itself, but a marker for a haplotype block that modulates ZFPM1 expression or splicing in hematopoietic and cardiac progenitor cells.

The Mechanism

FOG1 operates as both a co-activator and co-repressor, depending on the GATA partner it joins. In erythroid progenitors it co-activates GATA-1 target genes required for hemoglobin synthesis, including globin chain genes and heme biosynthesis enzymes. The pathway to nuclear localization is regulated: PI3K phosphorylates HSCB, which degrades the cytoplasmic anchor TACC3, freeing FOG1 to enter the nucleus and activate differentiation programs. When FOG1 is insufficiently active, cells accumulate in early progenitor stages, and mature erythrocytes emerging from the marrow carry less hemoglobin per cell²² less hemoglobin per cell
a lower MCH reflects smaller or less hemoglobin-dense red blood cells.

A secondary effect of reduced FOG1 activity is cholesterol dysregulation in developing erythroid cells: FOG1 normally represses the cholesterol transporters ABCA1 and LDLR during differentiation. Reduced FOG1 function allows excess cholesterol accumulation and increased membrane fluidity in the erythroid lineage, potentially compounding the hemoglobin-loading defect.

The same locus also tags variants affecting platelet biology: nearby LD partners (rs28634651, rs17175830) associate with plateletcrit and platelet count at genome-wide significance. In the cardiovascular system, ZFPM1's developmental role in endothelial-derived cardiac tissue appears to persist as a subtle influence on cardiac conduction — the locus associates with PR interval prolongation in a large multi-ancestry GWAS of electrocardiographic traits.

The Evidence

The strongest direct evidence comes from Vuckovic et al., Cell 2020³³ Vuckovic et al., Cell 2020
"The Polygenic and Monogenic Basis of Blood Traits and Diseases," 746,667 individuals, which identified rs12232375 as genome-wide significant for mean corpuscular hemoglobin (MCH, p = 7×10⁻²², beta = −0.072 SD), reticulocyte count, and plateletcrit. The effect on MCH — while modest in absolute terms — positions ZFPM1 alongside established erythropoietic regulators in an unbiased, replicated multi-population study.

The complementary trans-ethnic study Chen et al., Cell 2020⁴⁴ Chen et al., Cell 2020
746,667 individuals from 5 global populations confirmed the locus for platelet traits; LD partners near ZFPM1 showed one of the strongest platelet count signals (p = 1×10⁻⁵⁰) in the dataset, underscoring the gene's dual role in both red cell and megakaryocyte lineages.

Cardiac relevance was established by Ntalla et al., Nat Commun 2020⁵⁵ Ntalla et al., Nat Commun 2020
202 PR interval loci, multi-ancestry, which identified an LD partner at the ZFPM1 locus as significantly associated with PR interval duration (p = 2×10⁻¹²) — consistent with FOG1's documented requirement for proper cardiac morphogenesis Katz et al., PNAS 2003⁶⁶ Katz et al., PNAS 2003.

Separately, a meta-analysis of circulating VEGF levels found a genome-wide significant signal at 16q24.2 (rs4782371; p = 1.59×10⁻⁹), implicating ZFPM1-region variants in vascular endothelial signaling⁷⁷ vascular endothelial signaling
VEGF is critical for angiogenesis and vascular remodeling; reduced VEGF is associated with impaired wound healing and cardiovascular reserve.

Practical Actions

For most C-allele carriers, the MCH reduction is subclinical under normal dietary conditions; mean corpuscular hemoglobin typically stays within the normal reference range (27–33 pg) unless compounded by iron deficiency, vitamin B12 deficiency, or thalassemia trait. The actionable implications are:

Iron management: Lower MCH can be an early sign of iron-restricted erythropoiesis. C-allele carriers benefit from confirming their ferritin and serum iron are in the high-normal range, since ZFPM1-related MCH reduction will amplify any iron shortage. If MCH drifts below 27 pg, iron status should be evaluated before concluding the cause is genetic alone.

Cardiac monitoring: The PR interval association is subtle and clinical significance in heterozygotes is uncertain, but combined with other cardiac risk factors it adds incremental evidence for periodic ECG monitoring — especially relevant if the PR interval is already at the high-normal boundary (>160 ms).

Red cell indices context: Understanding that your lower-normal MCH has a partial genetic explanation prevents unnecessary clinical workups for iron deficiency when MCH is marginally low but ferritin is normal.

Interactions

ZFPM1 acts directly downstream of GATA-1/GATA-2 transcription factors. Variants in GATA1 (X-linked), GATA2, and their target genes interact with FOG1 activity. Rs28634651 (ZFPM1 locus, plateletcrit/PR interval) and rs17175830 (ZFPM1 locus, platelet count) are in partial LD with rs12232375 and collectively represent the haplotype block's effects on the erythroid- megakaryocyte-cardiac axis.

In patients with concurrent iron deficiency, the genetically-lower MCH from ZFPM1 variants and the nutritionally-lower MCH from reduced iron stores are additive — serum ferritin should be checked before attributing low MCH entirely to this variant.

Before a cell can respond to low cholesterol by making more, it needs to sense the deficit. That sensing job belongs to SCAP (SREBP cleavage-activating protein)¹¹ SCAP (SREBP cleavage-activating protein)
a seven-transmembrane sterol-sensing protein in the ER membrane that escorts SREBP transcription factors to the Golgi for proteolytic activation. When cholesterol is plentiful, SCAP is detained at the ER by INSIG proteins. When cholesterol drops, SCAP escorts SREBP-2 to the Golgi, where it is cleaved and activated — driving LDL receptor and HMG-CoA reductase expression to restore cholesterol supply. The rs12487736 variant changes valine to isoleucine at position 798 of SCAP, sitting within the WD-repeat domain that contacts SREBP-2. This amino acid substitution may subtly alter SCAP's interaction geometry with SREBP-2 and its response to cholesterol feedback signals.

The Mechanism

The SCAP Val798Ile substitution lies in the carboxy-terminal WD40 repeat region of SCAP, which mediates direct protein-protein contact with SREBP-2's regulatory domain. The functional consequence of this change is not yet fully characterized at the structural level, but population and clinical data suggest it shifts the SCAP–INSIG–SREBP-2 axis toward a state that promotes vascular cholesterol accumulation. In genome-wide expression profiling of 20 human atherosclerotic plaque samples (carotid, aortic, femoral) versus 6 control vessel samples²² genome-wide expression profiling of 20 human atherosclerotic plaque samples (carotid, aortic, femoral) versus 6 control vessel samples
Fan et al., Thrombosis Journal, 2008, SREBF-2 mRNA was significantly downregulated in carotid plaques (p=0.02), suggesting that reduced SREBF-2 transcriptional activity in inflamed vascular tissue — potentially exacerbated by SCAP functional variants — is a feature of established atherosclerosis rather than a compensatory response.

Under inflammatory conditions, the mTOR pathway activates the SCAP–SREBP-2 complex, increasing its translocation from the ER to the Golgi and driving excess LDL receptor expression and cholesterol uptake into vascular cells. SCAP knockdown in smooth muscle cells of ApoE-/- mice³³ SCAP knockdown in smooth muscle cells of ApoE-/- mice
Li et al., FASEB J, 2019 significantly reduced atherosclerotic plaque burden, confirming SCAP as a causal driver of lesion formation rather than merely a correlate. The rs12487736 variant, by modulating SCAP's functional state, may tilt this balance toward greater lipid accumulation in susceptible individuals — especially when co-inherited with functional variants in the SREBF2 gene itself.

The Evidence

The most compelling cardiovascular evidence comes from an autopsy-based study in 300 middle-aged Finnish men (ages 33–69) who died suddenly without prior diagnosed heart disease⁴⁴ autopsy-based study in 300 middle-aged Finnish men (ages 33–69) who died suddenly without prior diagnosed heart disease
Fan et al., Thromb J, 2008. Researchers genotyped SCAP 2386A>G (rs12487736) and SREBF2 1784G>C (rs2228314) and correlated genotypes with coronary artery narrowing and lesion characteristics. On its own, the SCAP G allele (plus-strand C at rs12487736) did not reach independent significance for SCD risk. However, men carrying both the SCAP G allele and the SREBF2 C allele had a 2.68-fold elevated risk of sudden cardiac death (OR 2.68, 95% CI 1.07–6.71; interaction p=0.046), pointing to a gene-gene amplification effect when both components of the SCAP–SREBP-2 circuit carry functional variants simultaneously.

Population-level data reinforce the pathway's relevance. A case-control study in 1,801 Han Chinese adults⁵⁵ A case-control study in 1,801 Han Chinese adults
Liu et al., Atherosclerosis, 2010 found three-locus interactions among SREBP2, SCAP, and INSIG1/2 variants significantly predicting coronary heart disease risk (p≤0.001). In pediatric cohorts, the variant also influences metabolic phenotypes: in 2,021 Chinese schoolchildren⁶⁶ 2,021 Chinese schoolchildren
Yang et al., PLoS One, 2017, rs12487736 was associated with both systolic BP (β=1.66, p=0.003) and diastolic BP (β=1.35, p=0.024), with a 36% elevated odds of high blood pressure in overweight/obese children carrying the risk allele (OR 1.36, 95% CI 1.02–1.82). The same variant interacts with dietary patterns to modulate blood pressure response, suggesting its effects are amplified under metabolic stress conditions.

A study of 614 HIV-positive individuals on antiretroviral therapy⁷⁷ study of 614 HIV-positive individuals on antiretroviral therapy
Lazzaretti et al., ScientificWorldJournal, 2013 also found the variant significantly associated with HDL-cholesterol levels, consistent with SCAP's broad role in sterol balance across lipoprotein fractions.

Practical Actions

For CC homozygotes, the most actionable implication is the additive risk when combined with the SREBF2 C allele (rs2228314). Checking both variants together informs a meaningful risk stratification that neither variant achieves alone. The variant's effect on LDL receptor regulation makes it relevant to statin pharmacology: SCAP-mediated SREBP-2 activation is a key mechanism by which statins amplify LDLR transcription. Variants that blunt this relay may partially attenuate the LDL-lowering response to standard statin doses, though direct pharmacogenomic evidence for this specific variant remains sparse.

For individuals with overweight or obesity, this variant's interaction with metabolic burden on blood pressure is an additional reason to track both blood pressure and lipid levels systematically, as the variant appears to act as a conditional risk amplifier in the context of metabolic stress.

Interactions

The critical interaction is with SREBF2 rs2228314 (Gly595Ala). SCAP is the direct chaperone and sterol sensor for SREBP-2. When both SCAP (Val798Ile, rs12487736) and SREBP-2 (Gly595Ala, rs2228314) carry functional variants, the entire cholesterol-sensing circuit is doubly compromised — the sensor that detects cholesterol (SCAP) and the transcription factor it activates (SREBP-2) both function suboptimally. The 2.68-fold SCD risk in Finnish men demonstrates that this co-inheritance is clinically significant.

INSIG1 and INSIG2 variants at the same pathway node also interact with SCAP variants in determining coronary heart disease risk in Chinese cohorts — the INSIG–SCAP–SREBP axis behaves as an integrated cholesterol sensing unit whose aggregate genetic load matters more than any single variant.

GLT6D1 (glycosyltransferase 6 domain containing 1)¹¹ GLT6D1 (glycosyltransferase 6 domain containing 1)
A gene on chromosome 9q34.3 in the GT6 glycosyltransferase family, which also includes the ABO blood group gene was the first gene ever identified through a genome-wide association study to influence susceptibility to aggressive periodontitis. The rs1537415 variant sits within intron 2 of this gene and was discovered in a landmark 2010 study of German and Dutch populations. It remains one of the strongest and best-replicated genetic risk factors for aggressive periodontitis identified to date.

Aggressive periodontitis (AgP)²² Aggressive periodontitis (AgP)
A severe, rapidly progressive form of gum disease that causes rapid destruction of the alveolar bone and connective tissue supporting the teeth, often in otherwise healthy young adults is distinct from ordinary gum disease. While chronic periodontitis is driven largely by plaque accumulation and poor hygiene, aggressive periodontitis has a strong genetic component, tends to cluster in families, and can destroy periodontal bone rapidly even with good oral hygiene. Understanding your genetic susceptibility opens the door to earlier intervention and targeted monitoring that can preserve teeth that might otherwise be lost.

The Mechanism

The rs1537415 variant does not directly alter a protein — it sits within an intron. Instead, it changes the binding landscape for transcription factors that control how much GLT6D1 is expressed. Functional studies using electrophoretic mobility shift assays³³ Functional studies using electrophoretic mobility shift assays
Laboratory technique that detects protein binding to specific DNA sequences revealed that the risk allele (C on the plus strand; reported as G in most papers, which use the minus/coding strand) substantially reduces binding of GATA-3⁴⁴ GATA-3
A transcription factor that acts as a master regulator of T helper 2 (Th2) cell differentiation, controlling the balance between anti-inflammatory and pro-inflammatory immune responses in T cells.

GATA-3 normally drives T cells toward a regulatory, anti-inflammatory phenotype that keeps periodontal inflammation in check. When the risk allele reduces GATA-3 binding, this brake on inflammation is weakened. The result is a shift in the T-cell response at the gum-tooth interface — toward greater pro-inflammatory activity, more aggressive immune attack on periodontal tissue, and accelerated bone loss. GLT6D1 is highly expressed in leukocytes and gingival tissue, confirming that the site of action is exactly where you would expect for a periodontitis susceptibility gene.

Interestingly, GLT6D1 may be functionally inactivated by a premature stop codon in its last exon in humans, suggesting that the gene's primary role in periodontitis susceptibility may be regulatory — influencing nearby gene expression or immune signaling architecture — rather than through the glycosyltransferase enzyme activity implied by its name.

The Evidence

The original 2010 GWAS by Schaefer et al.⁵⁵ The original 2010 GWAS by Schaefer et al.
A genome-wide association study identifies GLT6D1 as a susceptibility locus for periodontitis. Hum Mol Genet. 2010 combined German discovery and Dutch replication cohorts (n=1,758 total) and found rs1537415 at genome-wide significance (P=5.51×10⁻⁹, OR=1.59, 95% CI 1.36–1.86). The risk allele (C on plus strand) was present in ~48% of aggressive periodontitis cases compared to ~39% of healthy controls — a 10-percentage-point enrichment that is striking for a common variant.

Independent replication came from a Sudanese population in 2015⁶⁶ Independent replication came from a Sudanese population in 2015
Replication of the association of GLT6D1 with aggressive periodontitis in a Sudanese population. J Clin Periodontol. 2015, finding OR=1.50 (95% CI 1.04–2.17, p=0.03) in 132 AgP cases and 136 controls. When the Sudanese controls were supplemented with HapMap Yoruba data, the association strengthened to OR=1.56 (p=0.004). This cross-continental replication in a genetically distinct African population was important — it demonstrated that the association was not a European artifact.

A review by Masumoto et al. 2019⁷⁷ review by Masumoto et al. 2019 confirmed GLT6D1 as one of only three genes reaching genome-wide significance for aggressive periodontitis. Notably, the association has not been validated in Brazilian cohorts, possibly reflecting population stratification or differing admixture patterns. The specificity of the GLT6D1 signal for aggressive rather than chronic periodontitis makes rs1537415 particularly informative: it flags elevated risk for the more severe, rapidly progressive form of periodontal disease.

Evidence is rated strong: the finding has achieved genome-wide significance in the discovery cohort, has been independently replicated in two distinct populations, and has a plausible biological mechanism. It falls short of established because no clinical guidelines yet mandate genotype-guided periodontitis screening.

Practical Actions

People carrying the C risk allele — especially those with two copies (CC genotype) — should prioritize professional periodontal surveillance at shorter intervals than typical recommendations. Aggressive periodontitis often appears in adolescence or young adulthood, so early baseline assessment of periodontal bone levels (via periapical radiographs or cone beam CT) is particularly valuable. The earlier bone loss is detected, the more tissue can be preserved.

First-degree relatives of people diagnosed with aggressive periodontitis face elevated risk due to shared genetic factors — GLT6D1 risk allele carriage should prompt family-wide periodontal screening.

Regarding modifiable risk amplifiers: while the genetic variant cannot be changed, its inflammatory consequences can be modulated. Vitamin D deficiency has been consistently associated with worse periodontal outcomes across multiple studies, and given that GATA-3 signaling intersects with vitamin D receptor pathways in T cells, maintaining adequate vitamin D status is particularly relevant for carriers.

Interactions

The ANRIL locus (rs1333048) has been co-studied with GLT6D1 in aggressive periodontitis research and is also significantly associated with AgP in European populations. Both are independently associated and appear to act on different pathways (ANRIL influences cell cycle regulation and inflammation through NF-κB, while GLT6D1 acts through GATA-3 and T-cell polarization). Compound carriers of both risk alleles have not been formally studied in a large cohort, but would theoretically face additive risk.

The IL-10 locus (rs6667202) has also been associated with aggressive periodontitis in Brazilian populations and represents another immune-regulatory pathway. IL-10 is a key anti-inflammatory cytokine — when IL-10 is reduced (as with certain rs6667202 genotypes) and GATA-3 binding is also impaired (GLT6D1 risk allele), the periodontal immune environment may be doubly skewed toward inflammation.

Every time one of your cells divides, its entire genome must be copied with near-perfect fidelity. When copying errors create double-strand DNA breaks, a surveillance network activates to halt the cell cycle until repairs are complete. CHEK2 (checkpoint kinase 2) is a critical node in this network — it receives the damage signal from ATM¹¹ ATM
Ataxia telangiectasia mutated — the upstream kinase that detects double-strand breaks and phosphorylates CHEK2 to initiate cell cycle arrest and relays it to effectors including p53, BRCA1, and CDC25 phosphatases. The I157T variant doesn't destroy CHEK2's enzymatic machinery — it subtly corrupts the sensor domain that activates the protein in the first place, leaving a partially dysfunctional checkpoint that allows more damaged cells to escape surveillance and potentially become cancerous.

CHEK2 activates through a two-step process. First, ATM phosphorylates CHEK2 on threonine 68 in the SQ/TQ cluster domain. This phosphorylation is recognized by the FHA domain²² FHA domain
Forkhead-associated domain — a phosphopeptide-binding module that mediates protein-protein interactions through recognition of phosphothreonine residues; found in many DNA damage checkpoint proteins of a second CHEK2 molecule, driving homodimerization. The homodimer then undergoes autophosphorylation within the kinase domain, fully activating CHEK2 and releasing active monomers to phosphorylate downstream targets.

Isoleucine 157 sits at the center of the FHA domain's phosphopeptide-binding cleft. The I157T substitution replaces a nonpolar isoleucine with a polar threonine, disrupting van der Waals contacts at the FHA-kinase domain interface and reducing the affinity of the domain for phosphorylated binding partners. The result is a protein with essentially normal kinase activity in isolation but impaired activation — the I157T protein cannot efficiently dimerize in response to DNA damage signals, and in vitro studies³³ in vitro studies
Kilpivaara et al. Int J Cancer, 2004 confirm that it underperforms in substrate recognition and fails to mount a full response to ionizing radiation.

There is also a dominant-negative concern: CHEK2 operates as a homodimer. I157T protein can form heterodimers with wild-type CHEK2, potentially sequestering functional protein in non-productive complexes and reducing effective checkpoint activity below what would be expected from simple haploinsufficiency.

Unlike the CHEK2 1100delC frameshift (rs555607708), which destroys the kinase domain entirely and is unambiguously pathogenic, I157T is a partial loss-of-function variant. Its effects on cancer risk are real but smaller — this distinction has important implications for clinical management.

The variant was first associated with breast cancer⁴⁴ first associated with breast cancer
Kilpivaara O et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer, 2004 in a Finnish and Polish case-control study, finding I157T in 7.4% of breast cancer patients versus 5.3% of controls (OR 1.43, 95% CI 1.06–1.95). This study also provided the first functional evidence that I157T impairs the cellular response to ionizing radiation.

A comprehensive meta-analysis⁵⁵ comprehensive meta-analysis
Han FF et al. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol, 2013 pooling 18 case-control studies (26,336 cases and 44,219 controls) quantified the risk: OR 1.58 (95% CI 1.42–1.75) for breast cancer and OR 1.67 (95% CI 1.24–2.26) for colorectal cancer. Familial cases showed stronger associations (OR 1.85, 95% CI 1.51–2.26), consistent with a modifier gene acting on a background of other cancer-predisposing variants.

For colorectal cancer specifically, a systematic review⁶⁶ systematic review
Liu C et al. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2012 analyzing 4,029 cases and 13,844 controls found OR 1.61 for unselected colorectal cancer, rising to OR 1.97 for familial colorectal cancer cases.

Thyroid cancer is a notable I157T-enriched cancer type. A Polish study⁷⁷ Polish study
Siołek M et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer, 2015 found I157T in 13.3% of papillary thyroid cancer patients versus 6% of controls (OR 2.8). A separate Great Poland cohort⁸⁸ Great Poland cohort
Przybylska-Felus M et al. c.470T>C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma. Hered Cancer Clin Pract, 2015 confirmed a 2.7-fold increased thyroid cancer risk for I157T carriers, making thyroid the cancer type with one of the clearest I157T associations outside breast and colorectal cancer.

A particularly striking finding is the I157T association with adult-type ovarian granulosa cell tumors⁹⁹ adult-type ovarian granulosa cell tumors
Švadjlenka et al. CHEK2 p.I157T mutation is associated with increased risk of adult-type ovarian granulosa cell tumors. Cancers, 2022 — a rare ovarian cancer subtype. Among women with CHEK2 mutations, 36% of ovarian cancers were granulosa cell tumors (versus 1.3% in the general population), with a prevalence ratio of 26.5 for I157T specifically. This tumor type typically presents with abnormal uterine bleeding or abdominal symptoms, and the I157T association justifies awareness of this diagnosis in female carriers.

An interesting exception is lung cancer: a genome-wide study¹⁰¹⁰ genome-wide study
Wang Y et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet, 2014 found that CHEK2 I157T is associated with a reduced risk of squamous lung cancer (OR 0.38, p = 1.27×10⁻¹³). The mechanism for this protective effect is unclear — it may relate to differential CHEK2 function in squamous lung epithelial cells or to population structure effects — but it has been replicated and is one of the few genetically documented protective effects in cancer epidemiology.

Unlike the more severe CHEK2 1100delC frameshift, the I157T variant does not universally trigger high-risk surveillance protocols in isolation. Current NCCN and ACMG guidance (2024) indicates that I157T alone, without additional family history burden, does not meet the threshold for enhanced breast cancer screening beyond age-appropriate population guidelines. However, when family history includes first-degree relatives with breast, colorectal, thyroid, or prostate cancer, risk management should be personalized accordingly.

The most actionable implications of I157T are: (1) awareness of the multi-organ nature of the risk elevation — this is not just a breast cancer variant; (2) awareness that thyroid cancer risk appears consistently elevated across studies and annual neck palpation or thyroid ultrasound is a low-risk intervention; (3) standard colonoscopy surveillance beginning at age 45 is appropriate and, with a positive family history, consideration of earlier initiation at 40.

CHEK2 I157T operates in the same ATM→CHEK2→p53/BRCA1 checkpoint pathway as multiple other cancer-risk variants in the GeneOps database. CHEK2 is directly phosphorylated and activated by ATM (rs1801516, D1853N), so carriers of both I157T and ATM D1853N may have compounded attenuation of the DNA damage checkpoint. CHEK2 phosphorylates and stabilizes p53 (rs1042522, Pro72Arg affects p53 apoptotic function), so the combination of reduced CHEK2 signaling and a less-activating p53 variant could further elevate risk.

The other major CHEK2 variant in GeneOps, rs555607708 (1100delC), is a far more severe loss-of-function. Compound heterozygosity with 1100delC and I157T is theoretically possible but would be rare; functional data suggest that 1100delC's dominant effect would overshadow I157T's more modest impairment.

Transient receptor potential melastatin 8¹¹ Transient receptor potential melastatin 8
TRPM8 is a nonselective cation channel activated by temperatures below ~26 degrees C and by cooling compounds such as menthol and icilin. It belongs to the TRP superfamily of ion channels and is the principal cold thermosensor in mammals (TRPM8) is the body's primary cold-sensing ion channel, expressed in sensory neurons of the dorsal root ganglia²² dorsal root ganglia
Clusters of nerve cell bodies along the spinal cord that relay sensory information — including temperature, pain, and touch — from the periphery to the brain and trigeminal ganglia. The variant rs10166942 sits 950 base pairs upstream of the TRPM8 transcription start site and directly influences how much of this channel your sensory neurons produce. This regulatory position makes it one of the most robustly replicated migraine loci in all of human genetics — and an emerging link between cold sensation, pain processing, and metabolic thermogenesis.

The Mechanism

rs10166942 is a regulatory variant that alters transcription factor binding upstream of TRPM8. The C allele reduces TRPM8 expression from the chromosome that carries it. In human dorsal root ganglia tissue³³ human dorsal root ganglia tissue
Dourson AJ et al. Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans. Sci Rep, 2019, carriers of the C allele showed 47-99% lower TRPM8 mRNA expression compared to the T-carrying chromosome. This translates directly into altered cold sensing: C allele carriers required significantly lower temperatures to reach cold pain threshold (3.3 degrees C vs 6.5 degrees C, P=0.017) and took longer to reach that threshold (48.5 seconds vs 30.5 seconds, P=0.007).

The mechanism linking reduced TRPM8 to migraine protection involves the trigeminal pain pathway⁴⁴ trigeminal pain pathway
The trigeminal nerve innervates the face, head, and meninges. Overactivation of trigeminal sensory neurons triggers release of CGRP and other neuropeptides, causing neurogenic inflammation and the throbbing pain of migraine. TRPM8 activation in trigeminal neurons promotes release of calcitonin gene-related peptide (CGRP)⁵⁵ calcitonin gene-related peptide (CGRP)
The dominant neuropeptide in migraine pathophysiology. CGRP dilates cranial blood vessels and promotes neurogenic inflammation. All FDA-approved preventive migraine antibodies target CGRP or its receptor, the central neuropeptide of migraine. Less TRPM8 expression means less CGRP release upon cold or environmental temperature changes — and less migraine susceptibility.

The Evidence

The first GWAS to achieve genome-wide significance⁶⁶ first GWAS to achieve genome-wide significance
Chasman DI et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet, 2011 for rs10166942 included 5,122 migraineurs and 18,108 non-migraineurs, reporting an odds ratio of 0.85 (95% CI 0.82-0.89, P=5.5x10^-12) for the C allele. Gender-stratified analyses suggested the association may be stronger in women (meta-regression P=0.004). This was confirmed in a mega meta-analysis of 375,000 individuals⁷⁷ mega meta-analysis of 375,000 individuals
Gormley P et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet, 2016 and subsequently in a GWAS of 102,084 migraine cases⁸⁸ GWAS of 102,084 migraine cases
Hautakangas H et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet, 2022.

Beyond migraine frequency, the T allele drives chronification. A study of 1,904 migraine patients⁹⁹ 1,904 migraine patients
Alonso-Blanco C et al. TRPM8 genetic variant is associated with chronic migraine and allodynia. J Headache Pain, 2019 found T carriers were significantly more likely to have chronic migraine (33.7% vs 25.8%, adjusted OR 1.62, P=0.004) and showed greater allodynia severity (3.5 vs 2.6 on standard scales, P<0.001).

Evolutionary Context and Population Variation

rs10166942 shows one of the most extreme latitudinal clines in the human genome. The T allele frequency ranges from 5% in Nigeria to 88% in Finland — an FST value in the top 0.02%¹⁰¹⁰ FST value in the top 0.02%
Key FM et al. Human local adaptation of the TRPM8 cold receptor along a latitudinal cline. PLoS Genet, 2018 of all human genetic variation. Ancient DNA evidence places the onset of selection approximately 26,000 years ago during the last glacial maximum, suggesting TRPM8 upregulation (T allele) was advantageous for cold adaptation in high-latitude environments. The evolutionary cost of enhanced cold sensing appears to be increased migraine susceptibility — a trade-off that explains why migraine prevalence is highest in northern European populations.

The Metabolic Connection

Beyond pain sensing, TRPM8 plays a surprising role in energy metabolism. Mouse studies¹¹¹¹ Mouse studies
Ma S et al. Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity. J Mol Cell Biol, 2012 demonstrated that TRPM8 activation triggers UCP1¹²¹² UCP1
Uncoupling protein 1, the hallmark protein of brown adipose tissue. UCP1 dissipates the mitochondrial proton gradient as heat instead of ATP, driving non-shivering thermogenesis-dependent thermogenesis in brown adipose tissue through PKA-mediated phosphorylation. Dietary menthol (a TRPM8 agonist) prevented high-fat-diet-induced obesity and glucose intolerance in wild-type mice — effects completely absent in both TRPM8-knockout and UCP1-knockout animals. A follow-up study¹³¹³ follow-up study
Rossato M et al. Dietary menthol-induced TRPM8 activation enhances WAT browning and ameliorates diet-induced obesity. Oncotarget, 2014 showed that menthol also promotes browning of white adipose tissue, upregulating UCP1, PGC1-alpha, and PRDM16 expression.

This creates an intriguing dual profile for rs10166942: the T allele that increases migraine risk may simultaneously support greater thermogenic capacity and metabolic flexibility — consistent with the selection pressures of ice-age Europe. The C allele that protects against migraine may correspond to reduced TRPM8-mediated thermogenesis, though direct human metabolic studies linking this specific SNP to body composition are still needed.